



19 November 2024

ASX Announcement

MELBOURNE Australia, 19 November 2024: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) advises that its Annual General Meeting was held today at 9.00am AEDT.

The resolutions were voted in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange. In the Results of AGM announcement released earlier today, Resolutions 3, 11 and 13 incorrectly showed incomplete Proxy Votes on resolutions that were withdrawn as announced on 11 November 2024.

Revised disclosure of proxy votes are outlined on Page 3 and 4 of this announcement.

To subscribe to Island's monthly newsletter, [IslandWatch](#), and other forms of email communications, please visit [this page of our website](#).

Approved for release to the ASX by:

Dr David Foster
CEO and Managing Director
Island Pharmaceuticals Ltd
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue² fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA



approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automatic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.

Disclosure of Proxy Votes

Island Pharmaceuticals Limited

Annual General Meeting

Tuesday, 19 November 2024



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results	
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME	S250U APPLICABLE
1 Adoption of Remuneration Report	P	52,443,751	4,005,184 7.64%	48,363,567 92.22%	10,000	75,000 0.14%	4,080,184 7.78%	48,363,567 92.22%	10,000	-	Yes
2 Election of Christopher Ntoumenopoulos	P	69,049,614	67,079,755 97.15%	1,894,859 2.74%	55,000	75,000 0.11%	67,260,495 97.26%	1,894,859 2.74%	55,000	Carried	n/a
3 Re-election of Paul MacLeman	-	-	Resolution withdrawn						Not Carried	n/a	
4 Approval of increased placement capacity	P	69,049,614	56,834,352 82.31%	12,140,262 17.58%	55,000	75,000 0.11%	57,015,092 82.44%	12,140,262 17.56%	55,000	Carried	n/a
5 Ratification of prior issue of Broker Options	P	58,100,580	56,889,352 97.92%	1,136,228 1.96%	11,004,034	75,000 0.13%	57,070,092 98.05%	1,136,228 1.95%	11,004,034	Carried	n/a
6 Ratification of prior issue of Tranche 1 Shares	P	32,284,463	31,101,463 96.34%	1,108,000 3.43%	0	75,000 0.23%	31,282,203 96.58%	1,108,000 3.42%	0	Carried	n/a
7 Approval of issue of certain Tranche 2 Shares	P	32,229,463	20,042,429 62.19%	12,112,034 37.58%	55,000	75,000 0.23%	20,223,169 62.54%	12,112,034 37.46%	55,000	Carried	n/a
8 Approval of issue of certain Tranche 2 Options	P	32,229,463	20,025,201 62.13%	12,129,262 37.63%	55,000	75,000 0.23%	20,205,941 62.49%	12,129,262 37.51%	55,000	Carried	n/a



			Proxy Votes				Poll Results (if applicable)			Results	
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME	S250U APPLICABLE
9 Approval of issue of certain Tranche 2 Shares and Tranche 2 Options to Christopher Ntoumenopoulos	P	69,049,614	56,028,493 81.14%	12,916,121 18.71%	55,000	105,000 0.15%	56,239,233 81.32%	12,916,121 18.68%	55,000	Carried	n/a
10 Approval of issue of options to David Foster	P	52,398,751	51,162,853 97.64%	1,130,898 2.16%	55,000	105,000 0.20%	51,267,853 97.84%	1,130,898 2.16%	55,000	Carried	n/a
11 Approval of issue of options to Dr Paul MacLeman	-	-	Resolution withdrawn							Not Carried	n/a
12 Approval of issue of options to Albert Hansen	P	52,398,751	3,973,699 7.58%	48,320,052 92.22%	55,000	105,000 0.20%	4,078,699 7.78%	48,320,052 92.22%	55,000	Not Carried	n/a
13 Approval of issue of options to Anna Lavelle	-	-	Resolution withdrawn							Not Carried	n/a
14 Approval of issue of options to Christopher Ntoumenopoulos	P	52,398,751	49,583,320 94.63%	2,710,431 5.17%	55,000	105,000 0.20%	49,688,320 94.83%	2,710,431 5.17%	55,000	Carried	n/a
15 Spill Resolution (Conditional on the outcome of Resolution 1)	P	52,368,751	51,472,849 98.29%	820,902 1.57%	85,000	75,000 0.14%	51,547,849 98.43%	820,902 1.57%	85,000	Carried	n/a

